Robert L. van Nostrand, Director at Intra-Cellular Therapies, Inc. (ITCI), sold 40,000 shares at $76.07 ($3.0M) on 2024-06-18, disclosed to the SEC on 2024-06-21.
Scheduled sale ($3.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.71 | 8,891 | $673K | 22.2% |
| 2 | $75.71 | 8,891 | $673K | 22.2% |
| 3 | $76.07 | 11,109 | $845K | 27.8% |
| 4 | $76.07 | 11,109 | $845K | 27.8% |
| Total | $75.91 avg | 40,000 | $3.0M | 100% |
| Filing → |
| ITCI | SELL | 2023-04-19 | $630K | — | Filing → |
| ITCI | SELL | 2022-08-12 | $1.7M | — | Filing → |
| MBLX | BUY | 2012-12-04 | $21K | — | Filing → |